Regenxbio Plans RGX-202 BLA Filing for Q1 2027 and Maintains Cash Runway Through Q4 2027
During the Q3 2026 earnings call, Regenxbio (RGNX) management highlighted a significant transition toward commercialization. CEO Curran Simpson characterized the current period as an inflection point for the company, driven by upcoming regulatory milestones and preparations for bringing new therapies to market. A key focus of the company's pipeline is RGX-202, with plans to submit a full Biologics License Application (BLA) in the first quarter of 2027. To support these clinical and regulatory activities, Regenxbio reported a robust financial position, projecting a cash runway that extends into late Q4 2027.
Tickers: $RGNX
Topics: biotechnology commercialization earnings call regulatory approvals
Read the full article at Seeking Alpha
Part of the story Regenxbio Plans RGX-202 BLA Filing for Q1 2027 and Maintains Cash Runway Through Q4 2027 (2 articles)